Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Crinetics Pharmaceuticals stock opened at $34.51 on Tuesday. The company has a 50-day simple moving average of $36.10 and a 200-day simple moving average of $47.77. The firm has a market ...

Crinetics (CRNX) announced that the European Medicines Agency has validated the marketing authorization application for paltusotine, the first ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KalVista Pharmaceuticals (KALV – Research ...

Fintel reports that on March 25, 2025, Stifel initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with a Buy recommendation. Analyst Price Forecast Suggests 114.68% Upside As of March 19, ...

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted ...

DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24 th Annual Needham Healthcare Conference. Company ...

WASHINGTON, March 24 (Reuters) - U.S. President Donald Trump said on Monday he will in the very near future announce tariffs on automobiles, aluminum and pharmaceuticals. Speaking to reporters at ...